MAPK1 and non-small cell lung carcinoma: For instance, the pan-ErbB tyrosine kinase inhibitor (TKI) dacomitinib improves the sensitivity to topotecan in BCRP-overexpressing non small cell lung cancer cells by downregulating ERK activity without any modification in BCRP expression or activity [140].